ARS Pharmaceuticals, Inc.
NASDAQ:SPRY · NASDAQ Global Market
+$0.17 today
Vol 0.87M · Avg 1.71M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SPRY · Revenue to Net Income
Key Ratios
Analysis
$99.0M of revenue converted into -$198.0M of net income for the selected period. Gross margin is 76.0% and net margin is -214.3%, showing how much revenue survives after costs and taxes. EPS is $-2.01, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.3M -5.5% | $89.1M +297063.3% | $30.0K -97.7% | $1.3M -76.1% | $5.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $20.4M -0.7% | $20.6M | $0 -100.0% | $17.1M +7937.6% | $213.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $63.9M -6.9% | $68.6M +228540.0% | $30.0K +100.2% | -$15.8M -398.6% | $5.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 75.8% -1.2pp | 76.9% -23.1pp | 100.0% +1300.9pp | -1200.9% -1297.0pp | 96.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.2M -32.7% | $19.6M -3.4% | $20.3M +10.3% | $18.4M -9.4% | $20.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $230.1M | $0 -100.0% | $47.3M +153.5% | $18.7M +298.0% | $4.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $243.3M +239.5% | $71.7M +6.1% | $67.5M +242.7% | $19.7M -20.3% | $24.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M +1630.4% | $79.0K +8.2% | $73.0K -77.1% | $319.0K +49.8% | $213.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$167.4M -2101.3% | $8.4M +115.4% | -$54.3M -58.0% | -$34.4M -72.5% | -$19.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -198.6% -208.0pp | 9.4% +180982.7pp | -180973.3% -178362.2pp | -2611.2% -2249.3pp | -361.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$179.4M -5720.6% | -$3.1M +95.4% | -$67.5M -90.1% | -$35.5M -82.6% | -$19.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -212.9% -209.5pp | -3.5% +225063.2pp | -225066.7% -222367.9pp | -2698.8% -2345.5pp | -353.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.7M | $0 | $0 | $0 -100.0% | $800.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.6M | $0 | $0 | $0 -100.0% | $106.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $8.1M -29.0% | $11.4M -13.6% | $13.2M +1477.3% | $834.0K +205.7% | -$789.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$171.4M -2168.3% | $8.3M +115.2% | -$54.4M -56.8% | -$34.7M -71.3% | -$20.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -203.3% -212.6pp | 9.3% +181226.0pp | -181216.7% -178581.3pp | -2635.4% -2267.8pp | -367.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$80.0K -127.8% | $288.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$171.3M -2241.8% | $8.0M +114.7% | -$54.4M -56.8% | -$34.7M -71.3% | -$20.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -203.3% -212.2pp | 9.0% +181225.6pp | -181216.7% -178581.3pp | -2635.4% -2267.8pp | -367.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -2209.1% | $0 +114.5% | -$1 +34.5% | -$1 -24.3% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -2327.9% | $0 +113.7% | -$1 +34.5% | -$1 -24.3% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $98.6M +1.7% | $96.9M +1.8% | $95.2M +138.3% | $40.0M +38.4% | $28.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $98.6M -3.7% | $102.4M +7.5% | $95.2M +138.3% | $40.0M +38.4% | $28.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
GH Research PLC
NASDAQ:GHRS
$1.45B
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$1.29B
Savara Inc.
NASDAQ:SVRA
$1.08B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SPRY generate?
ARS Pharmaceuticals, Inc. (SPRY) reported $84.28M of revenue in fiscal 2025.
Is SPRY profitable?
ARS Pharmaceuticals, Inc. (SPRY) reported -$171,298,000.00 of net income, with a net margin of -203.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.